The management of age-related macular degeneration has rapidly progressed following the development of the anti-vascular endothelial growth factor (VEGF) ranibizumab. Ongoing trials are helping to define appropriate treatment schedules to optimise the use of ranibizumab in clinical practice.

Advances in the treatment of neovascular age-related macular degeneration / Lanzetta P. - In: EJHP PRACTICE. - ISSN 1781-9989. - 14:6(2008), pp. 17-20.

Advances in the treatment of neovascular age-related macular degeneration

LANZETTA, Paolo
2008

Abstract

The management of age-related macular degeneration has rapidly progressed following the development of the anti-vascular endothelial growth factor (VEGF) ranibizumab. Ongoing trials are helping to define appropriate treatment schedules to optimise the use of ranibizumab in clinical practice.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11390/848050
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact